Antiemetics Drugs Market By Drug Class (5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Dopamine Receptor Antagonists, Other Antiemetics); By Application (Chemotherapy-Induced Nausea and Vomiting (CINV), Post-Operative Nausea and Vomiting (PONV), Gastroenteritis and Acute Nausea, Pregnancy-Induced Nausea, Motion Sickness); By Route of Administration (Oral, Injectable, Transdermal, Other Routes); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Is the Antiemetics Drugs Market Evolving Across Oncology, Surgical Care, and Gastrointestinal Treatment? – (Updated On: 16th-Oct-2026)

The Global Antiemetics Drugs Market was estimated at USD 7.95 billion in 2025 and is projected to reach USD 12.30 billion by 2032, expanding at a CAGR of 6.43% during 2026–2032, according to Strategic Market Research.

 

In the United States, approximately 13.79 million prescriptions for ondansetron were issued to 7.29 million patients in 2024, according to prescription data updated in 2026. Ondansetron is commonly used to prevent nausea and vomiting, particularly during cancer treatment, after surgery, and for other medical conditions. The average prescription cost was USD 34.49, while the number of prescriptions increased by 10.3% compared to 2023. This increase reflects the growing use of antiemetic drugs in hospitals and outpatient care to help patients manage nausea and vomiting.

 

A 2025 international clinical study involving 401 chemotherapy patients showed that combining two antiemetic drugs, netupitant and palonosetron, helped prevent vomiting more effectively than standard treatment. Around 81% of patients receiving the combination experienced no vomiting and did not need additional medication, compared with 71.8% of patients receiving standard treatment. The findings highlight how combination therapies can improve nausea and vomiting management during chemotherapy. In December 2025, the U.S. FDA also approved tradipitant (Nereus) for treating vomiting caused by motion sickness, introducing another treatment option.

 

Overall, the Antiemetics Drugs Market is supported by the widespread use of ondansetron, the need to prevent vomiting during cancer treatment and surgery, and the development of more effective medicine combinations. Key opportunities include affordable generic medicines, injectable antiemetics used in hospitals, and newer treatments that help patients control nausea and vomiting more effectively.

 

Which Segments Are Leading the Antiemetics Drugs Market, and Where Are the Strongest Expansion Opportunities?

By Drug Class: Setrons Lead While NK1 Combinations Expand Delayed Symptom Control

Leading Subsegment: 5-HT3 Receptor Antagonists

5-HT3 Receptor Antagonists dominated the global Antiemetics Drugs Market with a 42% market share, contributing approximately USD 3.339 billion in 2025, and are projected to expand at a CAGR of 5.80% during 2026–2032. Commonly known as setrons, 5-HT3 receptor antagonists prevent nausea and vomiting by blocking serotonin activity at 5-HT3 receptors. Their widespread clinical use in chemotherapy-induced nausea and vomiting, postoperative care, and radiotherapy-related complications strengthens their market leadership, supported by established treatments such as ondansetron, granisetron, and palonosetron across healthcare settings worldwide.

Fastest-Growing Subsegment: NK1 Receptor Antagonists

The Neurokinin-1 (NK1) receptor antagonists accounted for 30% of the global market, equivalent to USD 2.385 billion in 2025, and are projected to achieve the fastest CAGR of 8.60% during 2026–2032. NK1 receptor antagonists prevent nausea and vomiting by blocking substance P from binding to NK1 receptors, thereby suppressing the vomiting reflex. Their effectiveness in preventing delayed chemotherapy-induced nausea and vomiting, particularly when combined with 5-HT3 receptor antagonists and corticosteroids, supports their expanding role in oncology supportive care and antiemetic treatment protocols.

 

By Application: Chemotherapy Supportive Care Shapes Antiemetic Utilization

Leading and Fastest-Growing Subsegment: Chemotherapy-Induced Nausea and Vomiting (CINV)

Chemotherapy-Induced Nausea and Vomiting (CINV) accounted for 47% of the global Antiemetics Drugs Market, contributing approximately USD 3.737 billion in 2025, and is projected to expand at a CAGR of 7.30% during 2026–2032. CINV represents a major clinical indication influencing antiemetic drug selection, administration timing, and combination therapy protocols. Its management involves serotonin (5-HT3) receptor antagonists, neurokinin-1 (NK1) receptor antagonists, and corticosteroids to prevent acute and delayed nausea and vomiting associated with chemotherapy, supporting treatment adherence and improving patient quality of life.

 

By Route of Administration: Oral Convenience and Rapid Injectable Relief Shape Treatment Selection

Leading Subsegment: Oral

The Oral segment accounted for 55% of the global market share, valued at approximately USD 4.373 billion in 2025, and is projected to grow at a CAGR of 6.10% during 2026–2032. Oral (PO) administration remains the preferred route for preventing and treating mild-to-moderate nausea and vomiting across outpatient, pediatric, and home-care settings. Its widespread adoption is supported by convenient dosing, ease of administration, availability of tablets and oral solutions, and suitability for managing chemotherapy-induced, postoperative, and medication-related nausea.

Fastest-Growing Subsegment: Injectable

The injectable antiemetics category accounted for 38% of the global Antiemetics Drugs Market, equivalent to USD 3.021 billion in 2025, and is projected to register the fastest CAGR of 7.20% during 2026–2032. Intravenous (IV) and intramuscular (IM) formulations play a vital role in managing acute and severe nausea and vomiting, particularly in emergency departments, oncology care, and postoperative recovery. Rapid therapeutic onset, precise dosing, and suitability for patients unable to tolerate oral medications strengthen their clinical importance across hospital-based treatment settings.

 

By Distribution Channel: Hospital Pharmacists Lead Therapy Management as Digital Access Expands

Leading Subsegment: Hospital Pharmacies

Hospital Pharmacies dominated the Antiemetics Drugs Market with a 49% market share, accounting for USD 3.896 billion in 2025, and are projected to expand at a CAGR of 6.80% during 2026–2032. Hospital pharmacies and clinical pharmacists play a pivotal role in antiemetic therapy management, particularly for chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and inpatient supportive care. Their responsibilities include optimizing drug selection, managing intravenous antiemetic formulations, monitoring treatment effectiveness, and implementing evidence-based protocols to improve patient outcomes and medication safety.

Fastest-Growing Subsegment: Online Pharmacies

Online pharmacies accounted for 8% of the Antiemetics Drugs Market in 2025, representing USD 0.636 billion in sales, and are projected to expand at the fastest CAGR of 8.50% during 2026–2032. Digital pharmacies support convenient access to antiemetics, medications used to prevent or treat nausea and vomiting associated with chemotherapy, surgery, motion sickness, and gastrointestinal disorders. Prescription fulfillment, home delivery, digital ordering, and improved access to recurring medications are strengthening the distribution channel’s role in antiemetic treatment management.

 

By Geography: North American Treatment Access and Asia-Pacific Oncology Expansion Shape Adoption

Leading Region: North America

North America accounted for the largest regional share of the Antiemetics Drugs Market, representing 39% and approximately USD 3.101 billion in 2025. The regional market is projected to expand at a CAGR of 5.60% during 2026–2032. Advanced healthcare infrastructure, widespread access to prescription medications, and adherence to clinical treatment guidelines support the adoption of antiemetic drugs. Oncology treatments, surgical procedures, and gastrointestinal disorders continue to drive the use of therapies designed to prevent and manage nausea and vomiting.

Fastest-Growing Region: Asia-Pacific

Asia-Pacific antiemetics drugs market accounted for 25% of the global market, valued at approximately USD 1.988 billion in 2025, and is projected to register the fastest regional CAGR of 8.30% during 2026–2032. Increasing emphasis on supportive oncology care, expanding chemotherapy services, and improving access to antiemetic medications are strengthening regional adoption. China, Japan, and India are contributing significantly through advancements in cancer treatment infrastructure, wider availability of serotonin receptor antagonists, and increasing clinical use of antiemetic therapies across hospitals and specialty healthcare facilities.

 

Which Companies Are Shaping the Competitive Landscape of the Antiemetics Drugs Market?

Merck & Co. — NK1 Receptor Antagonists and Chemotherapy Supportive Care

Merck & Co. has an established position in antiemetic therapy through EMEND (aprepitant and fosaprepitant), available in oral and intravenous formulations for preventing chemotherapy-induced nausea and vomiting. The company reported USD 65.01 billion in total worldwide sales in 2025, reflecting its substantial pharmaceutical operations, although this figure encompasses its complete portfolio.

In a Phase III clinical trial involving 1,001 patients receiving moderately emetogenic chemotherapy, the fosaprepitant-based regimen achieved a 78.9% complete response rate during the delayed phase, compared with 68.5% for the control regimen. This clinical evidence supports the role of NK1 receptor antagonists in improving delayed nausea and vomiting prevention.

Helsinn Healthcare — Fixed-Dose Combination Antiemetics

Helsinn Healthcare specializes in cancer supportive care through AKYNZEO (netupitant/palonosetron) and ALOXI (palonosetron). AKYNZEO combines NK1 and 5-HT3 receptor antagonism in a single treatment, addressing acute and delayed chemotherapy-induced nausea and vomiting.

The oral formulation combines 300 mg netupitant and 0.5 mg palonosetron, while its intravenous formulation contains fosnetupitant and palonosetron. A single AKYNZEO dose administered with dexamethasone can provide preventive coverage for up to five days following chemotherapy. In February 2026, Helsinn expanded its distribution and licensing agreement with ESTEVE into Austria, strengthening access to AKYNZEO and ALOXI in European oncology care.

Heron Therapeutics — Extended-Release and Injectable Antiemetic Technologies

Heron Therapeutics focuses on differentiated antiemetic delivery through CINVANTI (aprepitant injectable emulsion), SUSTOL (extended-release granisetron), and APONVIE (aprepitant injectable emulsion) for postoperative nausea and vomiting prevention.

The company reported USD 116.83 million in combined 2025 net revenue from these three antiemetic products. CINVANTI contributed USD 96.76 million, SUSTOL generated USD 8.50 million, and APONVIE reached USD 11.57 million. APONVIE revenue increased approximately 156.1% year over year, reflecting expanding utilization in surgical care. Heron's portfolio demonstrates opportunities for longer-duration symptom control and streamlined injectable administration.

Other Notable Companies and Their Market Roles

• GSK: Has a historical position in serotonin-antagonist antiemetic treatment through Zofran (ondansetron), contributing to the development and established clinical use of 5-HT3 receptor blockade.

• Cumberland Pharmaceuticals: Participates through SANCUSO, a granisetron transdermal patch designed to prevent chemotherapy-induced nausea and vomiting for up to five consecutive days, offering an alternative to oral administration.

 

Analyst Commentary: How Will Combination Regimens and Longer-Acting Formulations Shape Antiemetic Treatment?

The antiemetics drugs market is witnessing significant opportunities through the increasing use of combination antiemetic therapies, particularly NK1 receptor antagonists and 5-HT3 receptor antagonists, for managing chemotherapy-induced nausea and vomiting. Key opportunities include the adoption of long-acting formulations, improved oral and injectable drug delivery, and personalized antiemetic regimens. The growing emphasis on preventing delayed nausea and vomiting, alongside guideline-based supportive cancer care, is strengthening the clinical importance of effective antiemetic treatment.

 

Antiemetics Drugs Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 7.95 Billion
Revenue Forecast in 2032	USD 12.30 Billion
Overall Growth Rate	CAGR of 6.43% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Application, By Route of Administration, By Distribution Channel, By Geography
By Drug Class	5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Dopamine Receptor Antagonists, Other Antiemetics
By Application	Chemotherapy-Induced Nausea and Vomiting (CINV), Post-Operative Nausea and Vomiting (PONV), Gastroenteritis and Acute Nausea, Pregnancy-Induced Nausea, Motion Sickness
By Route of Administration	Oral, Injectable, Transdermal, Other Routes
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expanding chemotherapy treatment volumes, increasing adoption of combination antiemetic regimens, rising surgical procedures requiring postoperative nausea prevention, wider access to generic antiemetics, development of long-acting and injectable formulations
Customization Option	Available upon request